While the dollar amount is not large relative to market cap, the coordinated exit by two top executives immediately after exercising options may signal lack of near-term conviction. Traders should monitor for absence of offsetting buys and watch for upcoming earnings or clinical updates that could explain timing.
SYRE drugs
SYRE drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 1 $48.90entry
- T+1 · 8mo ago −2.70%α −2.78% · $47.58
- T+5 · 7mo ago +5.87%α +2.10% · $51.77
- T+20 · 7mo ago +47.01%α +37.29% · $71.89
- T+60 · 5mo ago +84.38%α +71.00% · $90.16
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two key executives at Spyre Therapeutics, the CFO and CMO, sold a combined $703K in open-market transactions on April 1, 2026, following derivative exercises. The sales represent a modest but notable insider selling cluster involving C-suite leadership.
Key Financial Metrics
Key Facts
- CFO Burrows Scott L sold 6,200 shares for $305,102 at $49.21 per share.
- CMO Sloan Sheldon sold 7,958 shares for $397,900 at $50.00 per share.
- Both executives also exercised in-the-money derivatives prior to selling, with no additional open-market purchases.
- Total open-market sale value: $703K, representing ~0.019% of $3.7B market cap, modest in size but significant due to C-suite participation.
- No insider buying was reported in the cluster.
Financial Impact
$703,000 in net insider selling by CFO and CMO
Risk Factors
- Perception of insider pessimism given no reinvestment or retention of shares post-exercise.
- Potential for negative market reaction due to C-suite selling, especially if no clear rationale is disclosed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-SYRE-1775266236001 |
Track record
36 reports on SYRE
8 of 11 bullish or bearish reports moved the stock their way by T+60. Best: +54.27% at T+60 after the Apr 13, 2026 report. 14 of 20 went positive at some point.
Filters
- Nov 3, 202613d ago 8-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Bearish 5/10 Entry $99.04 Now $99.37 −0.33% settles Feb 2
- Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
- Oct 9, 20265w ago SC 13D/A Neutral 3/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
- Oct 7, 20265w ago 8-K Bearish 5/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
- Oct 6, 20265w ago 424B5 Bearish 6/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
- Oct 5, 20266w ago Press Release Bearish 6/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 5, 20266w ago 424B5 Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 5, 20266w ago Press Release Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 2, 20266w ago Insider Cluster Bearish 4/10 Entry $92.72 Now $99.37 −7.17% settles Dec 30
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers